# A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

> **NCT06175767** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Mthera Pharma Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** MT101-5

## Key facts

- **NCT ID:** NCT06175767
- **Lead sponsor:** Mthera Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2025-07
- **Final completion:** 2025-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175767, "A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06175767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*